Investor Alert: Major Class Action Investigations on Recent Mergers Including VYNE, MASI, IBCP, and HCBN Monteverde & Associates PC is investigating significant mergers involving VYNE, MASI, IBCP, and HCBN, promising valuable information to shareholders.

Investor Alert: Major Class Action Investigations on Recent Mergers Including VYNE, MASI, IBCP, and HCBN #USA #New_York #Vyne #MASI #IBCP

Just Vyne loving some coffee!~
#oc #vyne #demongirl

VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement  VYNE Therapeutics (Nasdaq: VYNE) and Yarrow Bioscience entered a definitive all-stock merger; the combined company expects to operate as Yarrow Bioscience and trade on Nasdaq as YARW.A syndicate led by RTW Investments committed to pre-closing financings of approximately $200.0 million, and the combined company’s cash at closing is expected to fund operations into 2028. VYNE expects to declare a pre-closing cash dividend of about $14.5–$16.5 million to pre-merger VYNE stockholders.The combined company will advance Yarrow’s lead program, YB-101 (GS-098), into a U.S.-based Phase 1b/2b trial in H1 2026 with Phase 1b data expected in H2 2027; a Phase 1 TED trial is ongoing in China via partner GenSci.

#VYNE VYNE Therapeutics and Yarrow Bioscience Announce Merger Agreement 

www.stocktitan.net/news/VYNE/vyne-therapeut...

#VYNE VYNE Therapeutics Reports 2025 Third Quarter Financial Results and Provides Business Update

www.stocktitan.net/news/VYNE/vyne-therapeut...

Happy Halloween!!!
#halloween #brideoffrankenstien #oc #vyne #demongirl #monstergirl
#digitalart

Vyne Appoints Sajid Khan as President to Lead Healthcare Connectivity Revolution Sajid Khan, previously with Change Healthcare, joins Vyne as President of Vyne Intelligent Exchange, focusing on AI-powered healthcare connectivity.

Vyne Appoints Sajid Khan as President to Lead Healthcare Connectivity Revolution #United_States #healthcare #Indianapolis #Vyne #Sajid_Khan

VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update VYNE Therapeutics (Nasdaq: VYNE) reported Q2 2025 financial results and provided updates on its pipeline programs. The company ended Q2 with $39.6 million in cash, extending runway into first half of 2027. Net loss improved to $5.8 million ($0.13 per share) compared to $9.4 million ($0.22 per share) in Q2 2024.Key developments include promising efficacy signals for VYN202, their oral BD2-selective BET inhibitor, in psoriasis and other conditions. The FDA partially lifted a clinical hold on VYN202, allowing female enrollment while requiring additional toxicology data for male subjects. Their topical BET inhibitor, repibresib, missed primary endpoints in Phase 2b vitiligo trial, leading to trial termination. The company is now seeking a development partner for repibresib.

#VYNE VYNE Therapeutics Reports 2025 Second Quarter Financial Results and Provides Business Update

www.stocktitan.net/news/VYNE/vyne-therapeut...

NEWS: ( NASDAQ: #VYNE ) VYNE Therapeutics Reports Disappointing Phase 2b Results for Repibresib Gel in Vitiligo Trial, Shares Drop 73%

VYNE Therapeutics Reports Disappointing Phase 2b Results for Repibresib Gel in Vitiligo Trial, Shares Drop 73% VYNE Therapeutics Inc. (Nasdaq: VYNE) announced topline results from its Phase 2b trial evaluating Repibresib gel for the treatment of nonsegmental vitiligo, a

Nasdaq: #VYNE
#VYNETherapeutics shares plunge as Repibresib gel misses primary endpoints in Phase 2b vitiligo trial. Despite some signs of efficacy at the highest dose, VYNE is discontinuing the study and seeking a partner for further development.

prismmarketview.com/vyne-therape...

VYNE Therapeutics stock falls after vitiligo trial fails to meet endpoints Investing.com -- VYNE Therapeutics (NASDAQ:VYNE) stock fell 70% on Wednesday after the company announced its Phase 2b trial for repibresib gel in nonsegmental vitiligo failed to meet its primary and key secondary endpoints. The clinical-stage biopharmaceutical company reported that the trial did not achieve the primary endpoint of F-VASI50 (the proportion of subjects achieving at least 50% improvement in Facial Vitiligo Area Scoring Index) at week 24 compared to vehicle. The trial also missed a key secondary endpoint of F-VASI75. The company did note that nominally statistically significant effects were observed in some secondary and exploratory endpoints for the highest dose (3% concentration), including percent change from baseline in F-VASI score at week 24 compared to vehicle (-43.6% vs. -25.6%) and in T-VASI score (-28.3% vs. -16.2%). VYNE attributed the disappointing results to an "unusually high vehicle effect" and a higher-than-expected dropout rate in the active treatment arms (36.6% for the 3% concentration) compared to the vehicle arm (10.6%). "We are disappointed with the results of our Phase 2b trial, which were impacted by an unexpectedly high treatment effect in the vehicle arm and a high discontinuation rate in the active arms," said David Domzalski, President and Chief Executive Officer of VYNE. Following these results, the company announced it will terminate the extension phase of the trial and seek an external partner for continued development of repibresib. The trial evaluated 177 subjects across 45 sites in North America, testing three different concentrations (1%, 2%, and 3%) of repibresib gel against a vehicle control. Safety data showed a higher rate of treatment emergent adverse events in the treatment groups compared to vehicle, with application site pain being the most common side effect. VYNE reported it had approximately $39.6 million in cash, cash equivalents, and investments as of June 30, 2025. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #VYNE #Therapeutics #Investing #StockMarket #Biopharma

VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo VYNE Therapeutics (Nasdaq: VYNE) reported disappointing topline results from its Phase 2b trial of Repibresib gel for nonsegmental vitiligo. The trial, involving 177 subjects, failed to meet its primary endpoint of F-VASI50 and key secondary endpoint of F-VASI75 at week 24 compared to vehicle.Despite missing main endpoints, the 3% concentration showed nominally significant effects in secondary endpoints: -43.6% change from baseline in F-VASI score (vs. -25.6% vehicle) and -28.3% in T-VASI score (vs. -16.2% vehicle). Results were impacted by an unusually high vehicle effect and higher dropout rates in active arms (36.6% for 3% concentration vs. 10.6% for vehicle).The company will terminate the trial's extension phase and seek an external partner for Repibresib's continued development. VYNE reported approximately $39.6 million in cash and equivalents as of June 30, 2025.

#VYNE VYNE Therapeutics Announces Topline Results from Phase 2b Trial with Repibresib Gel in Nonsegmental Vitiligo

www.stocktitan.net/news/VYNE/vyne-therapeut...

VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202 VYNE Therapeutics (Nasdaq: VYNE) provided an update on its VYN202 program following an FDA clinical hold in April. The FDA has partially lifted the hold, allowing female patients to receive 0.25 mg and 0.5 mg doses in the Phase 1b psoriasis trial. The hold was initially placed due to testicular toxicity observed in dogs during non-clinical studies.Preliminary data from the small trial (n=7) showed promising results: PASI score improvements ranged from 27% reduction after 1 week to 90% reduction at week 8. Significant reductions in key inflammatory biomarkers were observed, and a patient with psoriatic arthritis showed meaningful improvement in joint pain. The company will discontinue enrollment in the Phase 1b psoriasis study, extending its cash runway into Q4 2026.

#VYNE VYNE Therapeutics Provides Program Update on Oral BET inhibitor VYN202

www.stocktitan.net/news/VYNE/vyne-therapeut...

Vyne and her cat(who’s name I can’t remember) just chilling~
#art #digitalart #vyne #demongirl #cat #chibi #cute
#oc

VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update VYNE Therapeutics (NASDAQ: VYNE) reported its Q1 2025 financial results and provided key updates on its pipeline. The company's lead candidate repibresib gel is progressing in a Phase 2b trial for vitiligo treatment, with top-line results expected in mid-2025. The trial involves approximately 180 patients testing three dose concentrations (1%, 2%, and 3%) against a vehicle control. However, VYNE's VYN202 program for psoriasis was placed on clinical hold by the FDA due to testicular toxicity observed in dog studies. Financially, VYNE reported $50.3 million in cash as of March 31, 2025, expected to fund operations into 2H 2026. The company posted a net loss of $8.6 million ($0.20 per share) compared to $6.2 million ($0.15 per share) in Q1 2024, with increased R&D expenses of $6.1 million primarily due to clinical trial costs.

#VYNE VYNE Therapeutics Reports 2025 First Quarter Financial Results and Provides Business Update

www.stocktitan.net/news/VYNE/vyne-therapeut...

VYNE shares tumble after FDA clinical hold on psoriasis drug study Investing.com -- VYNE Therapeutics (NASDAQ:VYNE) stock plummeted 20.2% following the company’s announcement that the U.S. Food and Drug Administration (FDA) has placed a clinical hold on their Phase 1b study of VYN202, a treatment for moderate-to-severe plaque psoriasis. This decision comes after an observation of testicular toxicity in dogs during a non-clinical toxicology study. The company, based in Bridgewater, New Jersey, has halted all screening, enrollment, and dosing of patients in the VYN202 trial. Despite this setback, VYNE has reported no serious adverse events in the subjects enrolled in the study thus far. VYNE’s leadership expressed their commitment to resolving the clinical hold swiftly and to continue discussions with the FDA. In contrast, the clinical hold does not affect VYNE’s ongoing Phase 2b trial of repibresib gel for nonsegmental vitiligo, which is a separate compound from VYN202. The company anticipates top-line results from the repibresib trial by mid-year. David Domzalski, President and CEO of VYNE, commented on the situation, "While we are disappointed by this unexpected development, the safety and well-being of patients in our studies is our top priority. We intend to work closely with the FDA to address the clinical hold as expeditiously as possible and we plan to provide additional updates pending continued engagement with FDA." In light of these events, H.C. Wainwright analyst Joseph Pantginis maintained a Buy rating on VYNE stock but reduced the price target from $5.75 to $4.50. Pantginis outlined several factors that could potentially hinder the company’s ability to reach the price target, including "failed or inconclusive clinical trials, the inability of the company to secure adequate funding to progress its products through the development pathway or the occurrence of dilutive capital raises, lack of commercial success, and de-listing risk." Investors are closely monitoring VYNE’s next moves as they navigate the challenges presented by the FDA’s clinical hold and strive to advance their product pipeline. This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.

Click Subscribe #VYNE #Psoriasis #FDA #ClinicalTrials #DrugDevelopment

VYNE Therapeutics Psoriasis Drug Trial Suspended: FDA Flags Critical Safety Issues in Animal Studies Key toxicity findings prompt FDA clinical hold on VYN202 psoriasis treatment. Separate vitiligo drug trial continues. Get crucial details about trial status and next steps.

#VYNE VYNE Therapeutics Provides Update on VYN202 Program

www.stocktitan.net/news/VYNE/vyne-therapeut...

6.) Vyne Vanadey
Au Ra • Xaela (Crow)
vyne.crd.co

#oc | #ffxiv | #gposer | #Vyne

Can VYNE's $61.5M War Chest Drive Success in Vitiligo and Psoriasis Trials? Strong $61.5M cash runway into 2026 supports Phase 2b vitiligo trial completion and new psoriasis study launch, despite wider losses from increased R&D investment.

#VYNE VYNE Therapeutics Reports 2024 Fourth Quarter and Year-End Financial Results and Provides Business Update

www.stocktitan.net/news/VYNE/vyne-therapeut...

Can This New Psoriasis Drug Revolutionize Treatment? VYNE's Latest Clinical Trial Reveals Key Details Novel BD2-selective oral treatment enters Phase 1b after successful early trials. Targeting multiple inflammatory pathways for chronic immune conditions.

#VYNE VYNE Therapeutics Initiates Phase 1b Trial of VYN202, a Novel BD2-Selective Oral BET Inhibitor, in Plaque Psoriasis

www.stocktitan.net/news/VYNE/vyne-therapeut...

A2A payments platform Vyne shuts down UK operations London-based Vyne is winding down its UK operations in the UK just months after the real-time account-to-account payments platform was acquired by Middle Eastern fintech Tarabut.

Ouch... 😢 #A2A #Payments Platform #Vyne Shuts Down UK Operations Just Months After Being Acquired by #Tarabut. UK Market Not Seen as Part of Current Growth Plans...
www.finextra.com/newsarticle/45400/a2a-pa...
#fintech #markets

Where are we heading after TikTok is gone!? I need an answer before the big day 😭 #tiktok #rednote #igreels #twitter #instagram #vyne

Just In: ( NASDAQ: #VYNE ) VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

VYNE Therapeutics Completes Phase 2b Trial Enrollment for Novel Vitiligo Treatment VYN201 VYNE advances VYN201 (repibresib) development with completed Phase 2b enrollment for nonsegmental vitiligo therapy. Top-line data expected mid-2025 for this potential breakthrough treatment.

#VYNE VYNE Therapeutics Completes Enrollment in Phase 2b Trial Evaluating VYN201 for the Treatment of Nonsegmental Vitiligo

www.stocktitan.net/news/VYNE/vyne-therapeut...

VYNE Therapeutics' Novel BET Inhibitor VYN202 Shows Breakthrough Safety Profile in Phase 1a Trial VYNE's BET inhibitor demonstrates promising safety data and once-daily dosing potential, marking significant progress in inflammatory disease treatment with no serious adverse events.

#VYNE VYNE Therapeutics Reports Positive Top-line Phase 1a MAD Data for VYN202, its Novel BD2-Selective BET Inhibitor

www.stocktitan.net/news/VYNE/vyne-therapeut...

Some art to distract my brain. Finished her up last night. Trying new things i guess. I feel like my coloring is pretty boring lately… so idk we will see if i keep it up or revert back to old habits. lol 🫠
(Do like how her booty turned out though) #oc #demon #vyne

Have a vyne wip~
#oc #demongirl #vyne

News; ( NASDAQ: #VYNE ) VYNE Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

#StockMarket #News

Vyne swinging into spring!~ took a a month to to finish but I’m really happy with it ❤️

#oc #demon #vyne

The Vyne lets you wear your iPhone or iPod touch, whether you want to is still up for debate It seems like wearing your gadgets is all the rage these days, and the Vyne is no exception. A belt-like flexible strip of plastic with a clip on the end for your iPod touch or iPhone (though we suppose it should work with any gadget that has the right dimensions), this product isn't wholly unlike the Gorillapod. There's no word on price or release date just yet, but just think of all the attention you'll get while using this in public. Then again, your hands will be free to do tons of other things -- like checking the time on your iPod nano wristwatch.

Claim your personal space in crowded places... (for more impact, use a backpack too) http://engt.co/fMx7PU #vyne #iphone